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Abstract Activation of protein kinase C (PKC) inhibits cell
cycle progression at the G1/S and G2/M transitions. We found
that phorbol 12-myristate 13-acetate (PMA) induced upregula-
tion of p21, not only in MCF-7 cells arrested in the G1 phase as
previously shown, but also in cells delayed in the G2 phase. This
increase in p21 in cells accumulated in the G1 and G2/M phases
of the cell cycle after PMA treatment was inhibited by the PKC
inhibitor GF109203X. This indicates that PKC activity is
required for PMA-induced p21 upregulation and cell cycle arrest
in the G1 and G2/M phases of the cell cycle. To further assess the
role of p21 in the PKC-induced G2/M cell cycle arrest
independently of its G1 arrest, we used aphidicolin-synchronised
MCF-7 cells. Our results show that, in parallel with the
inhibition of cdc2 activity, PMA addition enhanced the associa-
tions between p21 and either cyclin B or cdc2. Furthermore, we
found that after PMA treatment p21 was able to associate with
the active Tyr-15 dephosphorylated form of cdc2, but this
complex was devoid of kinase activity indicating that p21 may
play a role in inhibition of cdc2 induced by PMA. Taken
together, these observations provide evidence that p21 is involved
in integrating the PKC signaling pathway to the cell cycle
machinery at the G2/M cell cycle checkpoint.
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1. Introduction
Cell cycle progression requires the activation of di¡erent
cyclin-dependent kinases (CDKs), which are positively regu-
lated by cyclins and negatively regulated by CDK inhibitors
[1]. Two families of CDK inhibitors have been identi¢ed, one
family includes p16, p15, p18 and p19, which are speci¢c for
CDK4 and CDK6, and the other family contains p21, p27
and p57, with a broader speci¢city for CDKs [2]. Although
p21 is an universal inhibitor of CDKs, its growth inhibitory
e¡ect is largely exerted during the G1 phase of the cell cycle
by binding to CDK4 and CDK2 [3,4]. p21 also directly in-
hibits DNA replication in a PCNA-dependent manner [5].
Transient overexpression of p21 in tumour cells [6] and in
normal ¢broblasts [7] leads to an accumulation of cells in
the G1 phase of the cell cycle, whereas treatment with p21
antisense RNA promotes entry of quiescent cells into S phase
[8]. The p21 gene is induced by DNA damaging agents
through p53-dependent pathways [6,9]. The p21 gene can
also be up-regulated via p53-independent pathways by serum
stimulation [10] as well as in cellular senescence [11] and dif-
ferentiation [12,13]. In addition to this well characterised role
of p21 as an inhibitor of cell cycle progression in G1, recent
¢ndings are in favour of a role for p21 in G2 and mitotic
checkpoints. Firstly, during the cell cycle, p21 mRNA expres-
sion peaks in both G1 and G2/M phases [14]. In addition, p21
accumulates in the nucleus late in G2, concomitantly with
nuclear translocation of cyclin B, and is associated with cyclin
B/cdc2 and cyclin A/CDK2 [15]. Secondly, p21-inducible or
uninducible overexpression [16^19] results in an arrest of cells
in both G1 and G2/M phases of the cell cycle. Activation of
the mitotic checkpoint by damage to microtubules is also
associated with induction of p21 [20]. We have recently shown
that after microtubular damage, the association of p21 with
cyclin B/cdc2 complexes occurs in parallel with an inhibition
of cdc2 activity and mitotic exit [21].
Protein kinase C (PKC) isoenzymes are involved in growth
control at the G1/S and G2/M transitions as regulators link-
ing signal transduction pathways to the cell cycle machinery
review in [22]. PKC-mediated inhibition of growth results
from both a block of the cell cycle in G1 and a delay in the
transit through the G2 phase of the cell cycle [23,24]. PKC-
mediated cell cycle arrest in G1 is accompanied by accumu-
lation of the hypophosphorylated form of retinoblastoma pro-
tein due to inhibition of CDK2 activity [25,26]. Furthermore,
the two CDK inhibitors, p21 and p27, have been shown to be
mediators of the inhibition of CDK2 activity induced by
phorbol 12-myristate 13-acetate (PMA) [27,28]. p21 and p27
are also involved in the inhibition of CDK2 activity after
ectopic expression of PKC-R in NIH-3T3 cells [29]. The fact
that resistance of cancer cells to PMA has been associated in
some cases with a failure of this compound to increase p21
[30] is a further argument for a role of p21 in growth arrest
after PKC activation. Induction of p21 by PMA depends on
Raf-1 kinase and MAPK signaling pathways [30], but is medi-
ated by p53-independent pathways at the transcriptional level
[27]. The G2/M transition is also regulated by the PKC signal-
ing pathway. The delay in the G2/M transition induced by
PMA results from an inhibition in the activity of cdc2
[31,32]. Dephosphorylation of cdc2 on tyrosine residues by
cdc25 phosphatases allows cdc2 activation and entry of the
cell into mitosis. Inhibition of cdc2 activity after PMA treat-
ment has been found to be associated with down-regulation of
cdc25 phosphatase [32,33]. In the present study, we found that
in addition to its role in the G1 phase of the cell cycle, p21
contributes to the inhibition of cdc2 activity induced by PKC
activation in the G2/M phase of the cell cycle.
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2. Materials and methods
2.1. Cell culture and cell synchronisation
MCF-7 cells were obtained from the American Type Culture Col-
lection. Cells were grown in humidi¢ed 5% CO2/95% air at 37‡C in
RPMI 1640 medium supplemented with sodium bicarbonate (2 g/l),
2 mM glutamine, 1 WM insulin and 5% foetal calf serum. For cell
cycle synchronisation, MCF-7 cells were treated with aphidicolin
(1 Wg/ml) (Sigma) for 24 h to arrest the cells in the G1/S phase. Cells
were released from the G1/S cell cycle block by washing the cells three
times with phosphate-bu¡ered saline (PBS) and adding culture me-
dium containing 5% foetal calf serum in the presence or absence of
PMA (Sigma). At the indicated times, cells were either ¢xed and
prepared for £ow cytometric analysis of cell cycle parameters or har-
vested for determination of cdc2 activity and immunoprecipitations.
2.2. Flow cytometry
Aphidicolin-synchronised MCF-7 cells were treated with PMA. At
the indicated times, cells were washed in PBS then treated with 0.25%
trypsin-0.02% EDTA and harvested after removal of trypsin. After
centrifugation (300Ug, 10 min), the pelleted cells were ¢xed in 80%
ethanol overnight at 320‡C. The samples were centrifuged, washed
with PBS and resuspended in 10 Wg/ml of propidium iodide (Sigma)
and 0.1% RNase A (Sigma) in PBS. After a 15 min incubation at
37‡C, the distribution of cells in the di¡erent phases of the cell cycle
was determined by analytical £ow cytometry using LYSIS II software
(Becton Dickinson). For bivariate analysis of p21 and DNA contents,
cells were rinsed with PBS and suspended in 80% ethanol overnight at
320‡C as described by Darzynkiewicz et al. [34]. The samples were
then centrifuged, washed with PBS and treated with 0.25% Triton in
PBS for 5 min on ice. After addition of PBS and centrifugation, the
cells were incubated overnight at 4‡C in the presence of the mouse
monoclonal antibody to human p21 (Calbiochem) diluted 1:20 in PBS
containing 1% bovine serum albumin (BSA). Cells were washed and
incubated with a £uorescein 5-isothiocyanate FITC-conjugated goat
anti-mouse IgG antibody (Sigma) diluted 1:100 in PBS containing 1%
BSA. Cells were washed and resuspended in 10 Wg/ml of propidium
iodide and 0.1% RNase A in PBS and incubated for 15 min prior to
FACScan analysis. The control was prepared in an identical way
except that an isotype-speci¢c antibody (mouse IgG1 from Sigma)
was used instead of the p21 antibody. Cellular £uorescence was meas-
ured in a FACScan £ow cytometer (Becton Dickinson). The red (pro-
pidium iodide) and green (FITC) £uorescences from each cell were
separated and quantitated by the FACScan using the standard optics
and LYSIS II software (Becton Dickinson).
2.3. Western blotting, immunoprecipitation and kinase activity
Cells were washed with PBS and lysed in ice-cold lysis bu¡er (50
mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 1 mM DTT,
0.1% Triton, 50 mM sodium £uoride, 1 mM sodium orthovanadate,
100 Wg/ml PMSF and TPCK, 50 Wg/ml TLCK, 1 Wg/ml leupeptin,
pepstatin and aprotinin). Lysates were clari¢ed by centrifugation.
For Western blot analysis, 100 Wg of proteins were resolved by
SDS-PAGE and transferred to nitrocellulose membranes by semi-
dry blotting. The membranes were hybridised with p21 (Calbiochem)
antibodies. The blots were probed with actin antibody (Chemicon
International Inc.) for equal loading control. For immunoprecipita-
tion as for kinase activity determination, rabbit polyclonal cdc2 anti-
body was added to 1 mg of precleared cell lysates and incubated at
4‡C for 2 h on a rotating wheel. Immune complexes were recovered
with protein A-agarose (Pharmacia) and washed three times with lysis
bu¡er. For immunoprecipitation, immune complexes were separated
on 15% SDS-polyacrylamide gels as described above and a mouse
monoclonal p21 antibody (Calbiochem) or a mouse monoclonal
cdc2 (Transduction Laboratories) were used for immunoblot analysis.
For cdc2 kinase activity, beads were washed again with kinase assay
bu¡er (50 mM Tris-HCl pH 8, 10 mM MgCl2, 1 mM DTT). Phos-
phorylation of histone H1 was measured by incubating the beads with
30 Wl of a reaction mixture containing 100 WM ATP (Boehringer
Mannheim), 5 WCi [Q-32P]ATP (3000 Ci/mmol; New England Nuclear)
and 2 Wg histone H1 (Boehringer Mannheim) in kinase assay bu¡er
for 10 min at 30‡C. The reaction was stopped by boiling the samples
in Laemmli SDS sample bu¡er for 5 min, and samples were resolved
by 12% SDS-PAGE. The gels were dried and subjected to autoradiog-
raphy.
3. Results
3.1. p21 is induced after PMA treatment by PKC activation in
the G1 and G2/M phases of the cell cycle
In line with the ¢ndings of several groups [12,28,35], we
found that PMA induced a time- and a dose-dependent in-
crease in p21 protein level in MCF-7 cells (Fig. 1A). Six hours
after the addition of PMA (100 ng/ml) we observed a signi¢-
cant increase in p21 protein level which remained high until 48
h. We found that preincubation of MCF-7 cells with 0.5 WM
GF109203X, a compound which inhibits conventional PKCs
by interacting with the ATP binding site of this enzyme [36],
prevented the elevation of p21 protein induced by PMA (Fig.
1B). In parallel, we observed that GF109203X inhibited the
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Fig. 1. E¡ect of PKC activation on MCF-7 cells. A: Western blot
analysis of p21 protein after PMA treatment in MCF-7 cells. Total
cell lysates were prepared at various times after addition of PMA
(100 ng/ml). B: E¡ect of GF109203X on PMA-induced upregulation
of p21. MCF-7 cells were treated or not with PMA (100 ng/ml) for
24 h in the presence or absence of GF109203X (0.5 WM) added 2 h
before PMA. Total cell proteins were separated by SDS-PAGE and
transferred to nitrocellulose. Western blotting was carried out using
an antibody against p21. To control for the amount of proteins in
each lines, the same blot was probed with anti-actin mAb. C: E¡ect
of GF109203X on modi¢cations of cell cycle parameters induced by
PMA. Cell cycle parameters were analysed by £ow cytometry (a)
control MCF-7 cells; (b) cells treated with GF109203X (0.5 WM)
for 26 h; (c) MCF-7 cells treated with PMA (100 ng/ml) for 24 h;
(d) cells pretreated with GF109203X (0.5 WM) for 2 h and then
treated with PMA (100 ng/ml) and GF109203X for 24 h.
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PMA-induced accumulation of MCF-7 cells in the G1 and
G2/M phases of the cell cycle (Fig. 1C).
Since it now well established that p21 overexpression regu-
lates cell cycle progression in the G2/M phase of the cell cycle
[18,19], we investigated if p21 could be involved in the PKC-
induced regulation of the G2/M transition. Cells were thus
analysed by £ow cytometry for both DNA and p21 content.
A 24 h PMA treatment resulted in an elevation of p21 in cells
accumulated with G1 and G2/M DNA contents (Fig. 2). The
PKC inhibitor GF109203X (0.5 WM) inhibited the upregula-
tion of p21 protein in MCF-7 cells accumulated not only in
G1 but also in the G2/M phase of the cell cycle after PMA
addition (Fig. 2) indicating that PKC activation is involved in
regulation of p21 expression in G1 and G2/M phases of the
cell cycle.
3.2. Inhibition of cdc2 kinase activity in MCF-7 cells after
PMA treatment
To assess the PKC-induced G2/M cell cycle checkpoint in-
dependently of its G1 e¡ect, we synchronised MCF-7 cells at
the G1/S transition by treatment with aphidicolin (1 Wg/ml).
The cell cycle block induced by aphidicolin was released by
washing the cell monolayers and incubating them in fresh
medium. Analysis of the DNA content of MCF-7 cells after
release from the block indicated that MCF-7 cells entered S
phase within 3 h; most cells were in G2 after 6^9 h and had
returned to G1 between 12 and 15 h (Fig. 3A). In the presence
of PMA, applied at the time of aphidicolin release, we ob-
served a 6^9 h lag in the progression through the G2/M phase.
Most of the PMA-treated cells were in the G2/M phase be-
tween 6 h and 15 h (Fig. 3A) and entered G1 of the subse-
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Fig. 2. Bivariate analysis of p21 expression versus DNA content of either control MCF-7 cells, cells treated with GF109203X (0.5 WM) for 26
h, cells treated with PMA (100 ng/ml) for 24 h, cells treated with GF109203X (0.5 WM) and PMA for 24 h (GF109203X was added 2 h before
PMA). Isotypic control (IgG) done in parallel makes it possible to discriminate between speci¢c and non-speci¢c p21 £uorescence. Cells under
FITC channel 100 were considered p21-negative, cells above this channel were considered p21-positive.
Fig. 3. The e¡ect of PMA on aphidicolin-synchronised MCF-7 cells. MCF-7 cells were arrested at the G1/S transition by treatment with aphi-
dicolin (Aph) (1 Wg/ml) for 24 h. Cells were released from the aphidicolin block by washing and incubation in fresh medium. MCF-7 cells were
treated or untreated with PMA (100 ng/ml) at the time of aphidicolin release. Control and PMA-treated cells were harvested at various times
after aphidicolin release. A: FACS analysis of cell cycle parameters. B: cdc2 kinase activity associated with the immunoprecipitate of cdc2 was
assayed using histone H1 as a substrate.
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quent cell cycle within 18 h. This con¢rms that PMA transi-
ently inhibits cell cycle progression in the G2/M phase of the
cell cycle. Since active cdc2 is required for the G2/M transi-
tion, we investigated the activity of this kinase in MCF-7 cells
synchronised at the G1/S transition by treatment with aphidi-
colin. In control cultures, after aphidicolin release, kinase ac-
tivity rose to a peak at 12 h and declined between 12 h and
15 h when the majority of MCF-7 cells were in the G1 phase
of the subsequent cell cycle (Fig. 3B). In the presence of PMA
(100 ng/ml), the kinase activity detected 6 h and 9 h after
aphidicolin release was much lower than that observed in
the control cells. cdc2 kinase activity subsequently increased
indicating that this phenomenon was transient (Fig. 3B). We
observed that after PMA treatment the delay in the activation
of cdc2 paralleled the delay in the progression of cells into the
G2/M phase of the cell cycle.
3.3. p21 is involved in the regulation of cdc2 activity after
PMA treatment
p21 is an universal inhibitor of CDK. It inhibits G1 CDK
with a Ki of 0.5^15 nM, although it is less e¡ective towards
the cyclin B/cdc2 complex with a Ki of 400 nM [3]. Since
PMA led to an elevation in p21 in the G1 and G2/M phases
of the cell cycle (Fig. 2), p21 may participate not only in the
PMA-induced inhibition of CDK2, as previously shown [37],
but also in the inhibition of cdc2 activity. We therefore as-
sayed cyclin B and cdc2 immunoprecipitates from PMA-
treated MCF-7 cells for the presence of p21. We found that
PMA led to an elevation of p21 associated with cdc2 and
cyclin B immunoprecipitates (Fig. 4). The increase in p21
binding to cyclin B/cdc2 complexes was apparent at 6 h,
reaching a peak 9 h after PMA addition, indicating that this
increase preceded the lag in G2/M. Eighteen hours after aphi-
dicolin release, whereas PMA-treated cells were in the subse-
quent G1 phase, the association of p21 with cdc2 immuno-
precipitates decreased (data not shown).
In order to determine if the increasing associations of p21
with cyclin B/cdc2 complexes were responsible for the kinase
activity inhibition, we analysed further the nature of the cdc2
complexes, 12 h after aphidicolin release of control and PMA-
treated MCF-7 cells (Fig. 5). Despite the fact that cdc2 im-
mune complexes from control and PMA-treated cells contain
the same high proportion of the active tyrosine-dephosphoryl-
ated form, the kinase activity of cdc2 immunoprecipitates was
strongly reduced after PMA treatment; the inhibition of his-
tone kinase activity was correlated with the presence of a large
amount of p21 bound to cdc2. In parallel we showed that p21
immunoprecipitates from control PMA-treated cells were de-
void of histone kinase activity even though these complexes
contain the active form of cdc2 (Fig. 5). Western blot analysis
of p21 immunoprecipitates indicated that p21 was also asso-
ciated with the inactive tyrosine phosphorylated form of this
kinase. Binding of p21 to the active and inactive forms of cdc2
was higher after PMA treatment (Fig. 5). This result argues in
favour of a role of p21 in the PMA-induced inhibition of cdc2
activity and G2/M delay.
4. Discussion
p21 has been shown to be implicated in the regulation of
G1/S transition in response to various inhibitors of cell pro-
liferation including PMA. The results presented here indicate
that p21 also plays a role in integrating the PKC signaling
pathway in the cell cycle machinery at the G2/M cell check-
point. First, we found that PKC activation in MCF-7 cells
results in an increase of p21 not only in cells arrested in G1
but also in cells accumulated in the G2/M phase of the cell
cycle. Second, PMA inhibits cdc2 kinase activity and stimu-
lates binding of p21 to cyclin B/cdc2 complexes. Third, after
PMA treatment, p21-containing complexes were devoid of
histone H1 kinase activity.
A role of p21 in the cell cycle block in G1 induced by PMA
has been previously shown [12,35,37]. Furthermore it has been
shown that overexpression of PKC-R in NIH-3T3 cells indu-
ces an increase in the expression of both p21 and p27 and
their association with cyclin E/CDK2 [29]. PMA-induced in-
hibition of cell cycle progression in the G2 phase of the cell
cycle is known to be associated with inhibition of cdc2 kinase
activity [31,32]. Several molecular mechanisms come to mind
for the inhibition of cdc2 activity. The cyclin B/cdc2 complex
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Fig. 4. Time course analysis of in vivo association of p21 with cy-
clin B and cdc2 immunoprecipitates after PMA treatment. Cell ly-
sates were prepared from aphidicolin-synchronised MCF-7 cells
treated or not with PMA (100 ng/ml). 1 mg of total protein was im-
munoprecipitated (IP) with antibodies against cdc2, cyclin B and
p21. After immunoprecipitation, immune complexes were resolved
on SDS-polyacrylamide gels, and associated proteins were analyzed
by Western blotting (WB).
Fig. 5. p21-associated complexes are inactivated. Extracts were pre-
pared from control (3) and PMA-treated cells (+), 12 h after re-
lease from the aphidicolin block. 1 mg of total protein was immu-
noprecipitated (IP) with antibodies against cdc2 and p21. After
immunoprecipitation, immune complexes were either resolved on
SDS-polyacrylamide gels, and associated proteins were analysed by
Western blotting (WB), or tested for histone H1 kinase activity us-
ing histone H1 as a substrate.
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is inactivated as long as tyrosine 15 is phosphorylated, and
dephosphorylation of this residue by cdc25 phosphatases en-
ables cdc2 activation and entry into mitosis. It has been re-
ported that the G2/M arrest induced by PMA results from the
prevention of dephosphorylation of tyrosine residues in cdc2
due to a down-regulation of cdc25 expression [32,33,38]. In
the present study we did not observe a signi¢cant variation in
the proportion of phosphorylated inactive form of cdc2 in
PMA-treated MCF-7 cells compared to control cells indicat-
ing that, depending on the cell type, di¡erent mechanisms are
responsible for PKC-induced inhibition of cdc2 kinase activ-
ity. Another possibility is that a CDK inhibitor may be re-
sponsible for cdc2 inhibition. Indeed, a role for inhibitors of
CDK in the regulation of cell cycle progression in the G2/M
phase have been shown in several recent studies. Indeed, UV-
C irradiation of HeLa cells results in an accumulation of p16,
which correlates with S and G2 delays [39]. However, the
mechanism by which p16 regulates the progression in S and
G2 phases is not known. p21 is a universal inhibitor of CDKs
and it inhibits G1 CDK in vitro with a Ki value of 0.5^15 nM,
although it is less e¡ective toward the cyclin B/cdc2 complex
with a Ki of 400 nM [3]. Several observations argue in favour
of a role of p21 in other phases of the cell cycle than G1. p21
mRNA peaks in G1 and G2 phases of the cell cycle and p21
protein is found associated with cyclin B complexes during G2
[14]. At the G2/M boundary, p21 is bound to inactivated
cyclin A/CDK2 complexes and to a lesser extent to cyclin
B1/cdc2 complexes and these associations correlate with a
nuclear reaccumulation of p21 protein in late G2 [15]. We
have recently shown that p21 participates in the regulation
of mitotic exit after microtubule damage induced by paclitaxel
via an action on the cyclin B/cdc2 complex [21]. In the present
study, we found that PMA induced an increase in p21 native
protein level in MCF-7 cells transiently arrested in the G2/M
phase of the cell cycle. This upregulation of p21 was inhibited
by an inhibitor of conventional PKCs (GF 109203X) indicat-
ing that PKC activation is involved in p21 induction at the
G2/M transition in MCF-7 cells. It has recently been reported
that in Calu-1 and A549 cells which are insensitive to PMA-
induced G1 arrest, a G2/M cell cycle block is associated with
the appearance of a truncated form of p21 that lacks the C-
terminal epitope [40]. A similar truncated version of p21,
which was unable to associate with CDK2, has been also
observed in control and UV-irradiated transformed cell lines
[41]. In MCF-7 cells we did not ¢nd any evidence of the
appearance of a truncated form of p21 after PMA treatment.
The results of the present study argue in favour of a role for
p21 in the transient inhibition of the kinase activity of cyclin
B/cdc2 complexes induced by PMA in MCF-7 cells. However,
the increase in p21 could be a cause or a consequence of the
delay induced by PMA at this particular phase of the cell
cycle. The increase in p21 in immunoprecipitated cyclin B/
cdc2 complexes was parallel to the inhibition of cdc2 activity
and occurred before the delay induced by PMA on the G2/M
transition, suggesting that the increase in the association be-
tween p21 and cyclin B/cdc2 complexes was a cause rather
than a consequence of the cell cycle delay. p21-containing
cdk exist in both active and inactive states [42]. At a low
concentration p21 promotes the assembly of active cdk com-
plexes whereas at high concentrations it inhibits cdk activity
[42,43]. We observed here that whereas p21 was found asso-
ciated with the active dephosphorylated form of either cdc2 or
cyclin B, these complexes were devoid of histone kinase activ-
ity. This result argue in favour of a role of p21 in inhibiting
cdc2 kinase activity after PMA treatment. However, we can-
not exclude the possibility that some other mechanism partic-
ipates in the PKC-induced inhibition of cdc2 activity. Indeed,
it has recently been shown that irradiation and expression of
p53 in H1299 cells released from aphidicolin block result in a
very signi¢cant increase in p21 and an inhibition of cdc2 ac-
tivity, but, in this case, only a small proportion of total cdc2 is
complexed with p21 [44]. Furthermore, PMA may activate a
cdc2-independent signaling pathway in the regulation of the
G2/M checkpoint in di¡erent cell types. Indeed, in this re-
spect, inhibition of the PKCLII isoenzyme by chelerythrine
has been found to lead to a block of the cell cycle in G2,
which was due to an inhibition of PKC-mediated lamin B
phosphorylation and mitotic nuclear lamina disassembly
[45]. These observations show that the regulation of G2/M
transition involves a number of PKC-mediated pathways.
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